Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- HealthConnect OneHealthConnect One Names Brenda Reyes Senior Advisor for Global Maternal & Child Health PolicyIn its 40th year, the national birth equity organization extends its community-based model into global health policy; Reyes will attend the 15th Anniversary ROSE and ROBE Breastfeeding & Birth Justice Summit in New Orleans, August 26 through 29 CHICAGO, Aug. 19, 2026 --...
- Aurora Cannabis Inc.Aurora Cannabis Furthers Global Medical Cannabis Growth with Accretive Acquisition of Internode Pharma Limited and HAP Pharma Limited, Expanding Distribution Access to the UK Medical Cannabis MarketAurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce that it has acquired Internode Pharma Limited, a licensed importer and wholesaler, and...
- Summa Health Unveils Technology Transformation StackAKRON, Ohio, August 19, 2026--Summa Health and General Catalyst's Health Assurance Transformation Company (HATCo) today announced Summa's technology "stack", unveiling the first companies to partner with the system on its transformation plan. General Catalyst's HATCo acquired Summa Health in October 2025 with the vision of delivering a more proactive, accessible, and affordable system of community-based, lifelong healthcare. These companies are the first to come together to partner with the Akro
- Flatiron HealthFlatiron Health Brings Three Research Acceptances to WCLC 2026NEW YORK, August 19, 2026--Flatiron Health today announced its presence at the IASLC 2026 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, with three research acceptances highlighting real-world evidence that advances precision medicine and treatment optimization in non-small cell lung cancer (NSCLC). The presentations demonstrate how Flatiron's high-quality, longitudinal data reveals clinical insights that shape oncology decision-making acros
- AI-Powered Clinical Decision Support Market Size to Reach USD 9.95 Billion by 2035 | SNS InsiderThe U.S. market is projected to reach USD 2.23 Billion and Europe USD 2.42 Billion by 2035, driven by AI adoption and predictive analytics.
- Genome British ColumbiaBC health research pursues precision, genetics-based care for three conditionsGenome BC-funded projects cover off-the-shelf pharmacogenetic testing, genetically-informed nutrition planning, and predicting therapies for blood cancers.
- proteanTecs®proteanTecs Unveils Advanced Packaging Solutions to Improve Yield, Performance, and Reliability of Multi-Die SystemsHAIFA, Israel, August 19, 2026--proteanTecs®, the leading provider of deep data visibility for advanced electronics, today unveiled a dedicated suite of health, power and performance management solutions for multi-die systems. Based on the company’s unique on-chip monitoring technology, semiconductor and system companies can now improve yield, reduce risk and protect investments in high-value systems-in-package.
- ArcatoArcato Announces Phase 1 Clinical Trial Results and Closing of Fully Subscribed Financing Round--ARC-001 Gel demonstrates safety following third molar surgery-- --Exploratory analyses suggest durable analgesia as single dose ARC-001 Gel reduces post-operative pain within the first 24 hours and potentially for up to 1 week-- GREENVILLE, N.C., Aug. 19, 2026 -- Arcato...
- mPulsemPulse Introduces Inflection Points to Help Health Plans Turn Member Data into Timely, Personalized ActionLOS ANGELES, August 19, 2026--mPulse, a leader in Health Experience and Insights (HXI), today announced Inflection Points, an always-on engagement module within its HXI platform designed to help health plans identify meaningful changes in a member’s journey, determine the next right action, and trigger timely, relevant outreach when intervention can have the greatest impact on outcomes.
- Sterlington Advises Humata Health Founder and CEO on Acquisition by R1NEW YORK, August 19, 2026--Sterlington is advising Jeremy Friese, MD, Founder and Chief Executive Officer of Humata Health (Humata) in connection with the company’s acquisition by R1 RCM Inc., a leader in healthcare revenue management.
- U.S. ComplianceNew Leadership Framework Helps Organizations Build Stronger Workplace Safety CulturesDespite significant investments in safety programs, many organizations continue to struggle with one of the most difficult challenges in Environmental, Health and Safety (EHS): building a workplace culture where safety becomes part of everyday decision-making rather than simply another compliance requirement.To help address that challenge, U.S. Compliance (USC) has released Building a Strong Safety Culture: The 5 C's of Workplace...
- Hengrui Pharma Reports 2026 Interim Results as Innovation and Globalization Continue to Drive Business MomentumHengrui Pharma (“Hengrui” or “the Company”) today announced its financial results for the first half of 2026. During the reporting period, innovative drugs remained the Company’s key growth driver, while globalization initiatives continued to validate the global value of Hengrui’s innovation portfolio. Financial Highlights In the first half of 2026, Hengrui reported revenue of RMB15.46 billion. Drug sales revenue was RMB13.95 billion, representing a year-over-year increase of 1.87%. Innovative drug sales increased by 16.38% year-over-year and accounted for 63.16% of total drug sales, with non-oncology innovative drug sales increasing by 73.97% year-over-year and emerging as an increasingly important growth driver. Net profit attributable to shareholders of the listed company was RMB4.47 billion, up 0.34%. R&D investment totaled RMB4.61 billion, representing 29.8% of revenue. Pipeline and Regulatory Highlights Hengrui continued to advance its pipeline in China during the reporting period, obtaining seven innovation-related approvals, including two Class 1 innovative medicines, one Class 2 innovative medicine and four additional indications. At the end of the reporting period, nine marketing applications had been accepted for review by China’s National Medical Products Administration, while 17 clinical programs had advanced to Phase III, 22 to Phase II, and 10 innovative assets had entered Phase I clinical development. Hengrui also reported progress across its metabolic pipeline. Two Phase III studies of ribupatide injection, a GLP-1/GIP dual receptor agonist, in China for type 2 diabetes reported positive topline results, supporting a planned NDA submission. HRS-7535, an oral small molecule GLP-1 receptor agonist, met all primary and key secondary endpoints at Week 44 in a China Phase III obesity study, with continued weight loss through Week 50 and mean body-weight reduction of up to 11.1%. An NDA submission is planned. Global Partnerships and Business Development Hengrui continued to advance its globalization strategy through diversified collaboration models. Since 2023, the Company has completed 13 overseas business development transactions, including out-licensing, NewCo and strategic alliances, with a total potential transaction value of approximately US$42 billion. These collaborations include leading global pharmaceutical companies such as BMS, GSK and others. Among the diversified collaboration models Hengrui has explored, NewCo has also seen important progress in 2026. Kailera Therapeutics completed its Nasdaq IPO in April 2026, becoming one of the largest biotech IPOs at the time. Braveheart Bio also successfully listed on the Nasdaq Global Market on August 6, 2026. Scientific Recognition During the reporting period, 204 research findings related to Hengrui products were published in academic journals and received international recognition. Hengrui participated in the American Society of Clinical Oncology Annual Meeting for the 16th consecutive year, with 91 studies accepted, including 11 oral presentations—a new high for the Company. Research in non-oncology areas was also presented at major international congresses, including the American Diabetes Association, International Stroke Conference, World Congress of Nephrology, American College of Cardiology, American Academy of Dermatology, and European Alliance of Associations for Rheumatology. Outlook Looking ahead, Hengrui will continue to advance its innovation and globalization strategy, while further pursuing its dual-growth strategy across oncology and chronic diseases. The Company will strengthen its global R&D capabilities, pursue diversified international collaboration models, and continue to focus on delivering sustainable long-term value and bringing more high-quality innovative therapies to patients worldwide.